Manage Cookie Consent

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

FunctionalFunctional
Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

PreferencesPreferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

StatisticsStatistics

The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

MarketingMarketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

[Manage options](https://www.aiosyn.com/cookie-policy-eu-2/#cmplz-manage-consent-container) [Manage services](https://www.aiosyn.com/cookie-policy-eu-2/#cmplz-cookies-overview) [Manage {vendor\_count} vendors](https://www.aiosyn.com/cookie-policy-eu-2/#cmplz-tcf-wrapper) [Read more about these purposes](https://cookiedatabase.org/tcf/purposes/)

AcceptDenyView preferencesSave preferences [View preferences](https://www.aiosyn.com/cookie-policy-eu-2/#cmplz-manage-consent-container)

[Cookie Policy](https://www.aiosyn.com/cookie-policy-eu-2/) [{title}](https://www.aiosyn.com/#) [{title}](https://www.aiosyn.com/#)

Latest News: Aiosyn expands AI-powered quality control with incomplete scan detection [Learn more](https://www.aiosyn.com/news/aiosyn-expands-ai-powered-quality-control-with-incomplete-scan-detection/)

[![Aiosyn](https://www.aiosyn.com/wp-content/themes/ac-toolkit-theme/ac-toolkit-frontend/assets/actk-images/logo_dark.svg)![Aiosyn](https://www.aiosyn.com/wp-content/themes/ac-toolkit-theme/ac-toolkit-frontend/assets/actk-images/aiosyn-logo.svg)](https://www.aiosyn.com/)

[Contact](https://www.aiosyn.com/contact/)

# Precision _pathology_ for cancer and kidney diseases using AI

Aiosyn's pathology AI solutions help clinical laboratories, research organizations, and biopharma enhance their workflows and find the best possible treatment.

[Our solutions](https://www.aiosyn.com/#section-solutions)

![Aiosyn Homepage](https://www.aiosyn.com/cdn-cgi/image/width=3080,height=1894,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2025/01/Aiosyn-Mitosis-Breast-IVDR.png)

[Aiosyn Mitosis Breast](https://www.aiosyn.com/mitotic-figure-counting/) leverages deep learning to detect cell division in whole slide images, enhancing the efficiency and consistency of mitosis analysis for breast cancer grading. The application integrates with existing digital pathology software and can be deployed via cloud-based or on-premise installations, ensuring adaptability to diverse laboratory environments.

[Learn more](https://www.aiosyn.com/news/aiosyn-mitosis-breast-becomes-the-first-ai-powered-mitosis-detection-solution-to-achieve-ce-mark-certification-under-ivdr/)

We use science-based innovation to create AI-powered image analysis software, enhancing workflows and delivering certified solutions that have a positive impact on patients. Our computational pathology technology provides data-driven insights to improve clinical diagnostics and complement R&D studies.

By leveraging artificial intelligence (AI) to analyze whole slide images, our solutions can boost diagnostic accuracy and efficiency in digital pathology workflows.

For biopharma organizations, AI offers the potential to simplify and accelerate drug discovery and development.

- [![](https://www.aiosyn.com/metadata=none/wp-content/uploads/2023/03/life_sciences_home-scaled-new.jpg)\\
\\
**Life Sciences** \\
\\
Complement R&D studies and streamline review processes with  AI-powered image analysis.\\
\\
Learn more](https://www.aiosyn.com/solutions/life-sciences/)
- [![](https://www.aiosyn.com/metadata=none/wp-content/uploads/2023/03/clinical-diagnostic_home-scaled-1.jpg)\\
\\
**Clinical Diagnostics** \\
\\
Improve workflows and support clinical decisions with data-driven insights.\\
\\
Learn more](https://www.aiosyn.com/solutions/diagnostics/)

##### Seamless integration with existing workflows

Our modular software is tightly integrated

into standard pathology workflows,

ensuring a smooth and efficient transition.

[Learn more](https://www.aiosyn.com/book-a-demo/)

##### Rooted in the pathology practice

Our strong ties to clinical practice enable the co-development of deep learning solutions with pathology laboratories.

[More about Aiosyn](https://www.aiosyn.com/about/)

##### Built upon 20+ years of research experience

Founded as a spin-off from Radboudumc,

we combine state-of-the-art AI research and engineering to develop precision pathology solutions.

[Publications](https://www.aiosyn.com/news#publications/)

![Aiosyn Homepage](https://www.aiosyn.com/cdn-cgi/image/width=696,height=532,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2024/04/Working-ppl.png)

Collaboration with pathologists is crucial in developing AI tools, as is understanding and supporting their tasks and processes. At Aiosyn, we provide precision pathology solutions that inject deep learning algorithms into existing workflows, equipping medical professionals and researchers with data-driven insights. Our close connection to clinical practice enables us to build these solutions for and together with pathology labs and biopharma companies.

By co-developing our technology with experts and integrating modular software into standard workflows, we facilitate the adoption of digital pathology AI in clinical practice to improve patient outcomes worldwide.

[Join our pathology network](https://www.aiosyn.com/pathologists/)

- [![](https://www.aiosyn.com/cdn-cgi/image/width=1477,height=1011,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2025/04/Incomplete-scan-AiosynQC.png)\\
\\
**Aiosyn expands AI-powered quality control with incomplete scan detection** 09 April, 2025 •\\
By Anna Correas Grifoll\\
\\
Read more](https://www.aiosyn.com/news/aiosyn-expands-ai-powered-quality-control-with-incomplete-scan-detection/)
- [![](https://www.aiosyn.com/cdn-cgi/image/width=626,height=375,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2025/03/collaboration-techcyte.png)\\
\\
**Techcyte and Aiosyn collaborate to integrate AI-powered slide QC and mitotic counting into the Fusion™ digital pathology platform** 20 March, 2025 •\\
By Anna Correas Grifoll\\
\\
Read more](https://www.aiosyn.com/news/techcyte-and-aiosyn-collaborate-to-integrate-ai-powered-slide-qc-and-mitotic-counting-into-the-fusion-digital-pathology-platform/)
- [![](https://www.aiosyn.com/cdn-cgi/image/width=626,height=375,fit=crop,quality=80,format=auto,onerror=redirect,metadata=none/wp-content/uploads/2025/03/collaboration-pramana.png)\\
\\
**Aiosyn and Pramana introduce real-time AI processing for kidney biopsy assessments** 18 March, 2025 •\\
By Anna Correas Grifoll\\
\\
Read more](https://www.aiosyn.com/news/aiosyn-and-pramana-introduce-real-time-ai-processing-for-kidney-biopsy-assessments/)

[More news](https://www.aiosyn.com/news)

[![](https://www.aiosyn.com/metadata=none/wp-content/uploads/2025/02/Aiosyn-Mitosis-Breast-clinical-study.png)\\
\\
**AI-assisted mitosis counting in breast cancer. A large-scale validation study.** 25 March, 2024 • By Jeroen van der Laak\\
\\
Authors Leslie Tessier, Cristina González-Gonzalo, David Tellez, Wouter Bulten, Maschenka C.A. Balkenhol, Jeroen A.W.M. van der Laak. Abstract Introduction Expectations surrounding artificial intelligence (AI) in pathology are high. In contrast, little is known about the impact of AI on clinical...\\
\\
Read more](https://www.aiosyn.com/news/ai-assisted-mitosis-counting-in-breast-cancer-a-large-scale-validation-study/)

![Aiosyn](https://www.aiosyn.com/wp-content/themes/ac-toolkit-theme/ac-toolkit-frontend/assets/actk-images/aiosyn-logo-footer.svg)

At Aiosyn we are convinced that computational pathology empowers pathologists to make their work more accurate, efficient and effective. We develop software solutions that inject deep-learning algorithms into existing pathologist workflows to improve clinical decision-making.

- [Home](https://www.aiosyn.com/)
- [Life Sciences](https://www.aiosyn.com/solutions/life-sciences/)
- [Clinical Diagnostics](https://www.aiosyn.com/solutions/diagnostics/)
- [About](https://www.aiosyn.com/about/)
- [Support](https://aiosyn.atlassian.net/servicedesk/customer/portal/3)

- [Team](https://www.aiosyn.com/team/)
- [News and resources](https://www.aiosyn.com/news/)
- [Career](https://www.aiosyn.com/career/)
- [Contact](https://www.aiosyn.com/contact/)

**Toernooiveld 300**

**6525 EC Nijmegen**

**The Netherlands** [contact@aiosyn.com](mailto:contact@aiosyn.com)

![ISO 13485](https://www.aiosyn.com/wp-content/themes/ac-toolkit-theme/ac-toolkit-frontend/assets/actk-images/aiosyn-iso.png)

Copyright Aiosyn 2025. All rights reserved.


[Privacy policy](https://www.aiosyn.com/privacy-policy/) \|
[Cookie policy](https://www.aiosyn.com/cookie-policy-eu/)

Manage consent

[iframe](https://www.google.com/recaptcha/api2/anchor?ar=1&k=6LcnUFMfAAAAAGgS7Nb3_LnPwUkrKAL-f5LMQdhT&co=aHR0cHM6Ly93d3cuYWlvc3luLmNvbTo0NDM.&hl=en&v=jt8Oh2-Ue1u7nEbJQUIdocyd&size=invisible&cb=8o5tsbqrj39o)